Sixty billion dollars in Chinese pharmaceutical licenses changed hands in the first quarter of 2026, representing 69% of the global value of cross-border transactions according to Jefferies data. This figure says more about the state of global medical biology than any discourse on technological decoupling.
In less than a decade, China has become the primary supplier of pharmaceutical intellectual property to the American industry. Its laboratories produce the preclinical assets, trial data, and drug candidates that major groups like AstraZeneca, Pfizer, and Bristol Myers Squibb integrate into their pipelines. Unlike semiconductors, no machine, no oligopoly, no identifiable chokepoint structures this dependency. Which makes it both deeper and harder to contest.
The Essentials
- 60 billion dollars in cross-border Chinese licenses in the first quarter of 2026, representing 69% of global value according to Jefferies
- China represented 12.7% of global clinical trials according to ClinicalTrials.gov in 2023, or 39% when counting at least one Chinese site per trial according to Citeline; its cell therapy sector grows between 24% and 29% annually, compared to 17% to 23% globally
- No identifiable chokepoint enables targeted decoupling: biotech dependency is diffuse, contractual, and integrated into the pipelines of American laboratories
- A restriction on license flows threatens American patients as much as Chinese laboratories — which makes the politicization of this sector structurally more costly than for semiconductors
How Shanghai Became the Laboratory of the World
The story begins in the 2010s. While Washington debated Beijing’s technological rise, hundreds of researchers trained at American universities returned to China with rare capital: mastery of modern biology tools, connections to major American institutes, and the ability to work at operational costs incommensurable with their former employers.
They built companies. BeiGene, Zymeworks China, Zai Lab: names still little known to the general public, but whose assets now appear in the pipelines of the world’s largest pharmaceutical groups. The model is simple: Chinese teams conduct preclinical phases — molecular design, animal model testing, initial efficacy data — then cede development rights outside China to Western partners via licensing contracts. The Americans provide the capital for clinical development and distribution networks. The Chinese provide speed and volume.
The result: in 2023, China represented 12.7% of global clinical trials according to ClinicalTrials.gov, or 39% of trials initiated worldwide when counting at least one Chinese site per trial according to Citeline data — a figure that would have seemed fantastical a decade earlier. Progress in oncology and cell therapy is particularly striking, with the Chinese cell therapy sector estimated to grow between 24% and 29% annually across segments, compared to 17% to 23% globally according to analysts.
Biology Doesn’t Resemble Semiconductors
When Washington decided to slow China’s technological rise, it targeted what it knew how to cut: ASML’s lithography machines, TSMC’s advanced chips, semiconductor manufacturing equipment. The logic of chokepoints is clear in that domain. One component, one unique supplier, one physical border crossable by export decree.
Biotech doesn’t work that way. What China exports is knowledge embedded in molecules, patents, experimental protocols, and clinical databases. You don’t blockade a cargo of genomic sequences. You don’t seize a phase I trial data file. Pharmaceutical intellectual property circulates through contracts, emails, scientific publications, bilateral agreements between research teams. Its nature is immaterial, distributed, legal.
This is precisely what the lessons of decoupling in semiconductors don’t directly teach: where you can redirect a physical production chain to Vietnam or Mexico, you can’t relocate a scientific community in a few years. The critical mass of researchers, biobanks, patient data, and clinical infrastructure that China has accumulated doesn’t get rebuilt by decree.
What Major American Groups Have No Interest in Saying
The paradox is there, patent and little commented upon. American laboratories that publicly support a hard line on China are often the same ones who, in their presentations to investors, tout their licensing agreements with Chinese partners as markers of pipeline dynamism.
AstraZeneca has structured a significant portion of its oncology portfolio through partnerships in China. Pfizer negotiates licensing agreements with Shanghai laboratories for immunology assets. Bristol Myers Squibb, Merck, Johnson & Johnson: the list of groups engaged in Chinese cross-border transactions is virtually exhaustive of the pharmaceutical CAC and S&P indices. According to Jefferies, the value of Chinese licenses quintupled in three years.
This dependency has impeccable economic logic. A preclinical asset developed in China costs between one-third and one-fifth of the equivalent cost in the United States or Europe, for scientific quality now comparable on the majority of therapeutic indications. Refusing these assets means either slowing your pipeline or financing it at costs that increase the final prices paid by patients and insurers. Neither option is politically attractive.
The BIOSECURE Act and Its Real Limits
Washington hasn’t remained idle. The BIOSECURE Act, discussed in Congress since 2024 and finally integrated into the National Defense Authorization Act (NDAA) for fiscal year 2026 in December 2025, aims to restrict federal contracts with several Chinese biotechnology companies, including BGI Genomics and WuXi AppTec — the latter being one of the most used contract research service providers by American industry, and which was subsequently added to the Department of Defense’s 1260H list in June 2026.
The actual scope of the legislation illustrates precisely the difficulty. By targeting service providers rather than intellectual property licenses, the bill only touches part of the chain. WuXi AppTec is a research subcontractor: an American laboratory can replace it, laboriously, with an Indian or European equivalent. But assets from BeiGene or Zai Lab are not replaceable services: they are unique molecules, irreplicable patient data, sequences developed over several years. No legislative provision creates an alternative overnight.
Moreover, any restriction on license flows produces a mirror effect. If American groups can no longer buy Chinese preclinical assets, Chinese groups can no longer monetize those assets on Western capital markets. Beijing is not neutral in this equation: it has every interest in its laboratories remaining attractive to foreign partners, because this model finances their upgrade. Decoupling, in this sector, would penalize both parties symmetrically.
Public Health as an Adjustment Variable
There is a dimension that makes this debate even more delicate than that of semiconductors: human lives are directly at stake in industrial policy decisions.
In the chip war, a supply delay costs contracts and competitiveness. In the pharmaceutical license war, a slowdown in the oncology pipeline translates into reduced therapeutic options for patients with rare cancers or autoimmune diseases. Politicizing the sector requires explicitly assuming what the semiconductor debate didn’t have to verbalize: who decides that a potential therapeutic asset should not cross a border, and in the name of what higher interest?
This question has no technical answer. It is political in the fullest sense of the term. And the American Congress, which struggles to fund the National Institutes of Health at levels allowing it to rebuild domestic preclinical capacity, has not yet provided a coherent answer.
Here we find a tension analogous to what the fusion race illustrates between Western venture capital and Chinese planning: the United States excels at financing high-potential-return technological bets, but struggles to finance the long-term scientific base that makes those bets possible. China, for its part, decided that medical biology was a national priority and allocated resources to it accordingly, in a planned and sustained manner over time.
What China Understands That the West Struggles to Recognize
Beijing understood something essential: in twenty-first-century technological competition, the best safeguard against decoupling is not confrontation, it’s indispensability. China is not seeking to disconnect from the West in biotech. It is seeking to become so central to Western pipelines that decoupling becomes an option the West cannot afford.
This strategy has a name in economic literature: asymmetric interdependence. It consists of creating a dependency such that rupture costs the adversary more than oneself. In semiconductors, it is Taiwan that plays this role for advanced chips. In biotech, it is mainland China that is building this position for preclinical research.
The difference is that Taiwan is not seeking to build this indispensability deliberately: it results from a historical trajectory and a geographical accident. China’s position in biotech, meanwhile, is the product of deliberate industrial policy, financed by the state and executed over fifteen years.
What Will Need to Be Decided
The American debate on Chinese biotech runs into a limit that decoupling rhetoric doesn’t resolve: you cannot simultaneously want the best medicines for your citizens and refuse access to laboratories that produce the best assets currently available.
Two paths remain open. The first is massive investment in domestic preclinical capacity, through the NIH, university-industry partnerships, and visa policy that retains foreign researchers trained in the United States. Its cost is high and the timeframe for results is measured in decades, not quarters. The second is pragmatic engagement: maintain license flows while building safeguards on the most sensitive data, particularly genomic data from populations and clinical trial data related to defense.
Neither is a capitulation. Neither is a convincing decoupling narrative either. They share a premise that Washington has not yet officially assumed: that in biotech, as in other sectors with high scientific capital, interdependence with China is currently a structural fact, not an error to correct quickly.
The question that remains open is whether American industry can maintain its capacity for long-term innovation by sustainably relying on preclinical assets it no longer produces itself. The history of semiconductors suggests that total outsourcing of critical links ultimately weakens the entire chain. But it doesn’t indicate at what point this threshold is reached, or how to measure it before crossing it.
Sources
- Qatar Tribune / South China Morning Post – Jefferies: China’s $60bn biotech deal boom faces growing US pushback
- FierceBiotech – Jefferies Q1 2025 Report (32% of global value): China biotechs reshaping US biopharma outlicensing deals
- Nature/PMC – China’s share of clinical trials (12.7% according to ClinicalTrials.gov, 2023): PMC12280122
- Norstella/Citeline – 39% of global trials with a Chinese site in 2023: Spotlight China
- Grand View Research – China cell therapy market (CAGR 23.9%): Cell Therapy Market China
- Latham & Watkins – BIOSECURE Act becomes law (NDAA FY2026, December 2025): BIOSECURE Act becomes law
- Ropes & Gray – WuXi AppTec added to 1260H list (June 2026): DoD Updated 1260H List
- AstraZeneca – $15 billion investment in China through 2030 and oncology partnerships: AstraZeneca invests $15bn in China through 2030
- Pfizer – Licensing agreement with 3SBio (oncology, $6 billion): Pfizer enters exclusive licensing agreement with 3SBio